Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476944 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL2554949 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL13043948 | 0.83 | LDHA (0.36) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL28571485 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4572566 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL2805775 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4811341 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL964581 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4189346 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL10076082 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1MAPTFAAHMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350649-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. | 2024-10-24 | — | — | US | claimed |
| CN-119800361-A | Application method of TFT metal film etching solution | 昆山欣谷微电子材料有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20240350649-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | OCTAGON THERAPEUTICS, INC. | 2024-10-24 | — | — | US | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012054527-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110171267-A1 | ANTI-FUNGAL COMPOSITION | Immunitor USA, Inc. | 2011-07-14 | — | — | US | disclosed |
| US-7914799-B2 | Vaccine; heat deactivated antigen; induce immunology response | Immunitor USA, Inc. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2003018051-A1 | ANTI-FUNGAL COMPOSITION | JIRA VIC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20030039667-A1 | Anti-fungal composition | IMMUNITOR USA INC. | 2003-02-27 | — | — | US | disclosed |
| US-6191168-B1 | BACTERICIDES | Rubenstein, Edward | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | SMN1; SMN2 2361/4885ALDH1A1 796/4885MAPT 4181/4885 |
| US-20240350649-A1 | TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS RELATING TO ABERRANT IMMUNE CELLS | CD74, SERPINA6, CD2BP2 | SMN1; SMN2 3376/4885ALDH1A1 2933/4885MAPT 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.